SWM
MRNA icon

Sugarloaf Wealth Management’s Moderna MRNA Stock Holding History

Sugarloaf Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-222
Closed -$32K – 857
2022
Q2 		$32K Hold
222
– – 0.01% 352
2022
Q1 		$38K Buy
+222
New +$37.4K 0.01% 319
2020
Q2 		– Sell
-1,700
Closed -$51K – 710
2020
Q1 		$51K Buy
+1,700
New +$39.1K 0.02% 218

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sugarloaf Wealth Management's MRNA Position: Q3 2022 in Review

Sugarloaf Wealth Management sold out of Moderna (MRNA) in Q3 2022, closing a stake of 222 shares — an estimated $32K sold.

Sugarloaf Wealth Management first reported a position in MRNA in Q1 2020 and held it in 3 quarters. The position peaked at $51K in Q1 2020. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Sugarloaf Wealth Management reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 222 Moderna shares in Q3 2022, an estimated $32K.
  • Sugarloaf Wealth Management first reported a position in Moderna in Q1 2020 and held it in 3 quarters.
  • Sugarloaf Wealth Management's Moderna position peaked at $51K in Q1 2020.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2022, filed 11 Oct 2022.